PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

Low humoral responses to human cytomegalovirus is associated with immunological treatment failure among HIV infected patients on highly active antiretroviral therapy.

Abstract Human cytomegalovirus (HCMV) is one of the opportunistic infections associated with significant morbidity and mortality among HIV/AIDS patients especially before introduction of antiretroviral therapy (ART). Little is known regarding the humoral immune response against HCMV in relation to CD4 counts among HIV infected individuals. A total of 90 achieved sera from HIV infected patients attending Bugando Medical centre care and treatment centre (CTC) aged 18 years and above were retrieved and analyzed. Sociodemographic data were collected using structured data collection tool. Detection of specific HCMV antibodies was done using Indirect Enzyme Linked Immunosorbent Assay (ELISA). Data were analyzed by using STATA version 11. A total of 90 HIV infected patients were enrolled in the study whereby 36(40%) had immunological treatment failure. The mean age of the study participants was 39±12.3 years. The Prevalence of specific HCMV IgG antibodies was 84(93.3%, 95% CI: 88-98.5) while the prevalence of specific HCMV IgM antibodies was 2(2.3% 95% CI: 0.8-5.4). The median CD4 counts at 6 months and 12 months on HAART were significantly high in treatment success group. At 12 months of HAART as CD4 counts increases the HCMV IgG index value was also found to increase significantly, p=0.04. Significant proportion of HIV infected individuals was infected with HCMV. Higher median HCMV IgG titers were observed among patients with immunological treatment success. There is a need to investigate humoral immune responses in HIV infected individuals in relation to CD4 counts against various infectious diseases in developing countries where most of these infections are endemic.
PMID
Related Publications

Human cytomegalovirus (HCMV)-specific CD4+ T lymphocyte response in AIDS patients with no past or current HCMV disease following HAART.

Assessment of human cytomegalovirus specific T cell immunity in human immunodeficiency virus infected patients in different disease stages following HAART and in long-term non-progressors.

Rapid reconstitution of humoral immunity against cytomegalovirus but not HIV following highly active antiretroviral therapy.

Multiple relapses of human cytomegalovirus retinitis during HAART in an AIDS patient with reconstitution of CD4+ T cell count in the absence of HCMV-specific CD4+ T cell response.

Declining levels of rescued lymphoproliferative response to human cytomegalovirus (HCMV) in AIDS patients with or without HCMV disease following long-term HAART.

Authors

Mayor MeshTerms
Keywords

HCMV

HIV

IgG

immunological failure

Journal Title the pan african medical journal
Publication Year Start




PMID- 29515749
OWN - NLM
STAT- MEDLINE
DCOM- 20180313
LR  - 20180313
IS  - 1937-8688 (Electronic)
VI  - 28
DP  - 2017
TI  - Low humoral responses to human cytomegalovirus is associated with immunological
      treatment failure among HIV infected patients on highly active antiretroviral
      therapy.
PG  - 131
LID - 10.11604/pamj.2017.28.131.10480 [doi]
AB  - Human cytomegalovirus (HCMV) is one of the opportunistic infections associated
      with significant morbidity and mortality among HIV/AIDS patients especially
      before introduction of antiretroviral therapy (ART). Little is known regarding
      the humoral immune response against HCMV in relation to CD4 counts among HIV
      infected individuals. A total of 90 achieved sera from HIV infected patients
      attending Bugando Medical centre care and treatment centre (CTC) aged 18 years
      and above were retrieved and analyzed. Sociodemographic data were collected using
      structured data collection tool. Detection of specific HCMV antibodies was done
      using Indirect Enzyme Linked Immunosorbent Assay (ELISA). Data were analyzed by
      using STATA version 11. A total of 90 HIV infected patients were enrolled in the 
      study whereby 36(40%) had immunological treatment failure. The mean age of the
      study participants was 39+/-12.3 years. The Prevalence of specific HCMV IgG
      antibodies was 84(93.3%, 95% CI: 88-98.5) while the prevalence of specific HCMV
      IgM antibodies was 2(2.3% 95% CI: 0.8-5.4). The median CD4 counts at 6 months and
      12 months on HAART were significantly high in treatment success group. At 12
      months of HAART as CD4 counts increases the HCMV IgG index value was also found
      to increase significantly, p=0.04. Significant proportion of HIV infected
      individuals was infected with HCMV. Higher median HCMV IgG titers were observed
      among patients with immunological treatment success. There is a need to
      investigate humoral immune responses in HIV infected individuals in relation to
      CD4 counts against various infectious diseases in developing countries where most
      of these infections are endemic.
FAU - Mirambo, Mariam Mwinjuma
AU  - Mirambo MM
AD  - Department of Microbiology and Immunology, Weill Bugando School of Medicine, P.O.
      Box 1464, Mwanza, Tanzania.
FAU - Senyaeli, Ndealilia
AU  - Senyaeli N
AD  - Department of Microbiology and Immunology, Weill Bugando School of Medicine, P.O.
      Box 1464, Mwanza, Tanzania.
FAU - Mshana, Stephen Eliatosha
AU  - Mshana SE
AD  - Department of Microbiology and Immunology, Weill Bugando School of Medicine, P.O.
      Box 1464, Mwanza, Tanzania.
LA  - eng
PT  - Journal Article
DEP - 20171010
PL  - Uganda
TA  - Pan Afr Med J
JT  - The Pan African medical journal
JID - 101517926
RN  - 0 (Immunoglobulin G)
SB  - IM
MH  - AIDS-Related Opportunistic Infections/*immunology
MH  - Adult
MH  - Antiretroviral Therapy, Highly Active/*methods
MH  - CD4 Lymphocyte Count
MH  - Cytomegalovirus Infections/epidemiology/*immunology
MH  - Enzyme-Linked Immunosorbent Assay
MH  - Female
MH  - HIV Infections/*drug therapy/immunology
MH  - Humans
MH  - Immunity, Humoral
MH  - Immunoglobulin G/immunology
MH  - Male
MH  - Middle Aged
MH  - Tanzania
MH  - Time Factors
MH  - Treatment Failure
PMC - PMC5837160
OTO - NOTNLM
OT  - HCMV
OT  - HIV
OT  - IgG
OT  - immunological failure
EDAT- 2018/03/09 06:00
MHDA- 2018/03/14 06:00
CRDT- 2018/03/09 06:00
PHST- 2016/08/04 00:00 [received]
PHST- 2017/06/07 00:00 [accepted]
PHST- 2018/03/09 06:00 [entrez]
PHST- 2018/03/09 06:00 [pubmed]
PHST- 2018/03/14 06:00 [medline]
AID - 10.11604/pamj.2017.28.131.10480 [doi]
AID - PAMJ-28-131 [pii]
PST - epublish
SO  - Pan Afr Med J. 2017 Oct 10;28:131. doi: 10.11604/pamj.2017.28.131.10480.
      eCollection 2017.